Why your Alzheimer’s disease study is going to fail

Key Points

• Many Alzheimer's disease studies fail due to inadequate study design, impacting results significantly.
• Key evidence shows that about 70% of trials do not meet their primary endpoints, demonstrating a major issue.
• Assessment using biomarkers and clinical trials highlights the complexity of developing effective interventions.
• This analysis may enable improved study designs in Alzheimer's research for better outcomes.